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Statistical Methods for Automated Drug Susceptibility
Testing: Bayesian Minimum Inhibitory Concentration
Prediction from Growth Curves
Xi Zhou, Merlise A. Clyde, James Garrett, Viridiana Lourdes,
Michael O’Connell, Giovanni Parmigiani, David J. Turner, and Tim Wiles ∗
Abstract
Determination of the minimum inhibitory concentration (MIC) of a drug that pre-
vents microbial growth is an important step for managing patients with infections. In
this paper, we present a novel probabilistic approach that accurately estimates MICs
based on a panel of multiple curves reflecting features of bacterial growth. We develop a
probabilistic model for determining whether a given dilution of an antimicrobial agent
is the MIC given features of the growth curves over time. Because of the potentially
large collection of features, we utilize Bayesian model selection to narrow the collection
of predictors to the most important variables. In addition to point estimates of MICs,
we are able to provide posterior probabilities that each dilution is the MIC based on
the observed growth curves. The methods are easily automated and have been incor-
porated into the Becton-Dickinson PHOENIX automated susceptibility system that
rapidly and accurately classifies the resistance of a large number of micro-organisms
in clinical samples. Over seventy-five studies to date have shown this new method
provides improved estimation of MICs over existing approaches.
Key Words: Bayes, BIC, decision theory, logistic regression, model selection, model uncer-
tainty
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1 Introduction
Since the discovery of penicillin in the late 19th century, microbiology has undergone rapid
development. Large number of antibiotics have been identified and have greatly improved
the management of patients with infectious diseases. Identification and susceptibility testing
of clinically obtained isolates are performed daily in clinical laboratories across the world.
Rapid and accurate identification of micro-organisms and especially their drug resistance
is critical for the management of patients. Speedy reporting of these testing results have
been shown to have clinical and financial benefits not only to patients but also to clinical
laboratories (Barenfanger et al. 1999).
Despite such rapid progress, routine laboratory susceptibility testing methods still take
24 hours to provide results. Current methods for antimicrobial susceptibility testing (AST)
are largely phenotypic approaches based on the growth patterns of the micro-organisms in
antimicrobial agents (Wheat 2001). The minimum inhibitory concentration (MIC) is defined
as the lowest concentration above which bacterial growth is inhibited in vivo testing. The
MIC value is then utilized to determine the clinical effectiveness of a given antibiotic for
the isolate being tested. The interpretation of the MIC is reported as susceptible (S) if the
combination is likely to be effective (a low MIC value) and resistant (R) if treatment failure
is likely (a high MIC value). In some cases an intermediate result is reported when the MIC
value falls between the S and R values.
Efforts for speeding up the process of susceptibility testing have resulted in the develop-
ment of automated AST systems. With automation, a large number of tests can be performed
at the same time and the amount of the data to be analyzed increases. There is a crucial
need, however, for developing statistical methods that produce reliable MIC estimates from
such systems. In this paper, we develop a novel real-time statistical method that allows
more accurate and rapid determination of MICs based on a panel of growth curves for a
2
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given isolate exposed to various dilutions of an anti-microbial agent. This methodology is
currently implemented in Becton Dickinson’s (BD) newly developed PHOENIX AST system
(BD Diagnostic Systems, Sparks, MD). This system provides rapid and reliable susceptibility
testing of a majority of clinically encountered bacterial strains and is currently utilized by
a large number of hospitals across the globe. To date, more than seventy-five recent studies
have shown good reliability of this AST system in MIC estimation and breakpoint deter-
mination for various micro-organisms and drugs (see Fahr et al. 2003; Donay et al. 2004;
Horstkotte et al. 2004, for example).
In the next section, we describe the structure of the panel growth data obtained during
the development of the BD PHOENIX AST system. Our goal is to identify and use features
of the growth curves to accurately predict the MIC for each set of panel data. In order
to train the statistical algorithms, in section 3 we develop a model that predicts for each
concentration a growth or no growth response, using available features of the curves from
each panel. Features in the growth data that are crucial for predicting the probability of
growth are selected using Bayesian model selection. For each isolate and drug dilution in
a panel, we construct an estimate of the probability of growth using these selected features
of the growth curves. In Section 4, we present a novel method to combine the estimated
growth probabilities for the sequence of drug dilutions in a panel to construct a probability
distribution for the MIC. A decision theoretic approach for estimating the MIC is presented
which balances the different types of errors in making an MIC call. In Section 5, we validate
the method and illustrate its performance using two selected antibiotics, piperacillin and
cefoxitin. We conclude with discussion in Section 6.
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2 The PHOENIX AST System
PHOENIX is an instrumented antimicrobial susceptibility testing (AST) system for rapid
identification and susceptibility determination of clinical samples. In this system, a biological
sample is placed in each of eight wells on a test panel, where each panel is a single PHOENIX
diagnostic disposable cartridge. Multiple panels are placed in a revolving carousel and at a
sequence of twenty minute intervals the system moves the panels past a detector where red,
green, and blue wavelengths are directed at each well. The system measures the resulting
wavelengths that emanate from the wells; these optical measurements are used to generate
two measures of microbial growth: the redox state and turbidity characteristics of the sample
wells which are directly correlated with microbial growth. The redox state of a sample in a
well is measured by utilizing the change in red, green and blue readings that occurs over time
as a result of the reduction of a growth indicator, such as resazurin, by the antimicrobial
material in the well. As the resazurin is reduced, the color of the sample in the well changes
from blue to red to clear. This change in redox is represented numerically as a continuum,
with the value 0 indicating an unreduced growth indicator (blue=resazurin), the value 0.5
indicating that the indicator is 50% reduced (red=resazurin), and the value 1.0 indicating
that the indicator has been completely reduced (clear=dihydroresorufin). The turbidity is
also estimated by using the red, green and blue readings. The initial signal has a value of
0 and a maximum of 2.25 units can be estimated. The units for turbidity correspond to
McFarland units.
The system monitors growth over time to decide if the samples have incubated long
enough to estimate the MIC. If the processor determines that the maximum redox state for
the growth control well of the test panel is greater than 0.07 but less than a predetermined
value of 0.2, the panel continues to be incubated, unless the elapsed incubation period
has exceeded 16 hours. In this case, the test panel is failed as having insufficient sample
4
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growth, and no results are reported for that test panel. If the processor determines that the
maximum redox state for the growth control well is indeed greater than 0.2, the processor
then determines whether the redox curve for the growth control well indicates that the sample
is a slow or fast growing sample or not yet classifiable as either a slow or fast growing sample.
In the latter case, panel incubation continues and the panel is retested twenty minutes later
as discussed above. However, if the processor determines the curve classification is either
fast or slow growing, the time at which this occurs is labeled as the “time-to-result” and
the turbidity and redox data for each of the wells in the panel are extracted. A second-
degree polynomial local regression algorithm (LOESS) is used to smooth the time series
data for both redox and turbidity values calculated for each well over the elapsed period of
time. From the LOESS fit any reading at any time point can be estimated. Moreover, first-
and second-derivatives can be estimated at any point as a function of fitted local regression
coefficients.
Figure 1 illustrates these interpolated growth curves for three PHOENIX panels in
which three gram-negative bacterial strains were combined with eight dilutions of the drug
piperacillin (PIP). Each curve corresponds to a different dilution of the drug PIP. The verti-
cal line represents the time-to-result, the time at which features are extracted for determining
the MIC. Independently from the PHOENIX AST system, a reference MIC is determined
for each strain. In Figure 1, all curves corresponding to dilutions greater than the reference
MIC are colored red, while all curves with dilutions less than or equal to the reference MIC
are colored blue. The dilution corresponding to the reference MIC is illustrated with a blue
dashed line.
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3 Modelling Probability of Growth
Theoretically, we should see no growth in a well with a concentration higher than the true
MIC. For our purposes, we will treat the reference MIC as the truth as this is the best
available information. Using this external reference value of the MIC, we create a binary
response variable Yij for dilution (curve) j in panel i defined as
Yij =


1 if dilution j is < Reference MIC
0 if dilution j is ≥ Reference MIC.
This definition treats the reference MIC data as if it were measured without error and
ignores any possible miss-classifications of curves. Inspection of the panels in the second
row in Figure 1 indicates that several curves with dilutions below the reference MIC exhibit
growth. Upon further verification, in this case the problem is not an error in the reference
MIC data, but is conjectured to be related to the formulation of the panel where the actual
concentrations of drugs in the wells are less than their nominal values. The predictive
accuracy of the training model may possibly be improved through an iterative procedure
by omitting such “outlier” panels that exhibited strong growth for dilutions below the MIC
when the reference MIC could be verified as being correct.
3.1 Models
Conditional on the unknown probabilities (and MIC), we assume that indicators of growth
in different wells and across panels are independent of each other,
Yij | piij
ind
∼ Ber(piij) i = 1, . . . , n, j = 1, . . . , J (1)
6
http://biostats.bepress.com/jhubiostat/paper163
where piij is the probability of growth or equivalently that dilution j in panel i is less than
the MIC, n is the number of panels, and J is the number of wells in a panel (J = 8). While
it is conceivable that observations in the same panel may be dependent, this assumption
implies that such dependence may be captured through a model for the probabilities piij, for
example, a panel specific random effect.
The indicator of GROWTH/NO GROWTH may be predicted as a function of the growth
curves by modelling the probabilities of growth, piij , as a function of the time series for
dilution j in panel i. While of course the entire time series could be used for modeling the
GROWTH indicators, certain features of the curves may be sufficient for differentiating the
pattern of GROWTH/NO GROWTH. In an experiment with no noise in the growth curves,
we would actually need only the difference in growth measurements from the beginning to
the time-to-result to separate the dilutions corresponding to GROWTH or NO GROWTH.
However with noisy curves, it is not that simple and other features may be better predictors of
growth. In Table 3.1, we list the features of the curves that were viewed as being scientifically
relevant for predicting growth. These include the difference in growth, the area under the
growth curve, the first derivative, the second derivative at the time-to-result and time points
where maxima occurred. Most features are defined relative to the growth control well to
standardize them across different isolate/drug combinations.
We use a logistic regression model, a generalized linear model (GLM), to relate the
GROWTH indicator to the collection of features, where the linear predictor ηij ≡ logit(piij) ≡
log(piij/(1− piij)) is expressed as a linear function of selected features. As we are uncertain
that the relationship is actually linear in the features in Table 3.1, we may try more flexible
GLM models where we replace the linear functions by up to a third order polynomial in each
feature. As the linear, quadratic, and cubic terms are typically highly correlated with each
other, orthogonal polynomials are preferable from a computational perspective for model
selection, but give equivalent predictions. More generally, the GLM can be represented in
7
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FEATURE LABEL DESCRIPTION
T.FD Turbidity, 1st derivative of the Test Well
T.SD Turbidity, 2nd derivative of the Test Well
T.IN Turbidity, Integral of the Test Well
T.AB.M Turbidity, Maximum Absolute of the Test Well
T.FD.M Turbodity, Maximum 1st Derivative of the Test Well
T.SD.M Turbidity, Maximum 2nd Derivative of the Test Well
T.AB.M.R T.AB.M(Test Well)/T.AB.M(Control Well)
T.FD.M.R T.FD.M(Test Well)/T.FD.M(Control Well)
T.SD.M.R T.SD.M(Tets Well)/T.SD.M(Control Well)
T.IN.R T.IN(Test Well)/T.AB(Control Well)
T.FD.T tT.FD.M(Test Well) - tT.FD.M(Control Well)
T.SD.T tT.SD.M(Test Well) - tT.SD.M(Control Well)
R.FD Redox, 1st derivative of the Test Well
R.SD Redox, 2nd derivative of the Test Well
R.IN Redox, Integral of the Test Well
R.AB.M Redox, Maximum Absolute of the Test Well
R.FD.M Redox, Maximum 1st Derivative of the Test Well
R.SD.M Redox, Maximum 2nd Derivative of the Test Well
R.AB.M.R R.AB.M(Test Well)/R.AB.M(Control Well)
R.FD.M.R R.FD.M(Test Well)/R.FD.M(Control Well)
R.SD.M.R R.SD.M(Test Well)/R.SD.M(Control Well)
R.IN.R R.IN(Test Well)/R.AB Control Well)
R.FD.T tR.FD.M(Test Well) - tR.FD.M(Control Well)
R.SD.T tR.SD.M(Test Well) - tR.SD.M(Control Well)
Table 1: Characteristic features of growth curves used as covariates in the GROWTH or NO
GROWTH model.
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matrix notation as η = Xβ, where X represents the n× p matrix of feature variables with
columns for the linear, quadratic and cubic terms, β is the p dimensional vector of the
unknown regression coefficients and η is the n-dimensional vector of the linear predictor.
Once we have estimates of β, these are used to calculate ηˆij , the estimate of the linear
predictor, which in turn is used to obtain the estimates of the probabilities of GROWTH,
pˆiij =
exp(ηˆij)
1 + exp(ηˆij)
.
We may find that not all features are needed to model the probability of GROWTH;
the variables represent features that could potentially explain the growth patterns and in
some cases may be redundant. Using all features (and the higher polynomial terms) may
lead to over-fitting of the model training data, and poor predictions on the out of sample
validation data. Reducing the set of features is also important because of limited storage
and computing capacity in the system for making predictions. Bayesian variable selection
(Hoeting et al. 1999; Clyde and George 2004) can be used to reduce the set of features to
prevent over-fitting while still providing excellent out-of-sample properties.
3.2 Bayesian Model Selection
We used Bayesian model selection based on the Bayes Information Criterion (Schwarz 1978;
Kass and Raftery 1995) to reduce the set of features used in the prediction of GROWTH.
This approach is equivalent to using a penalized deviance criterion for model selection,
however the penalty depends on the sample size, which ensures that in large samples that the
probability of the true model goes to one (under modest conditions), and provides consistent
model selection (Kass and Raftery 1995). This choice typically results in more parsimonious
models than selection based on, for example, the often-used Akaike’s Information Criterion
(AIC) (Akaike 1973, 1983a,b).
9
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Models M correspond to different choices of features and polynomials in the features
used to capture the smooth functions. Using BIC, the probability of a model, Mm, given
the collection of panel data Y = {Yij}i=1,...,n,j=1,...8 is approximated by
p(Mm|Y) =
exp(L(Mm)−
dm
2
log(n))∑
m′ exp(L(Mm′)−
d
m
′
2
log(n))
where L(Mm) is the log likelihood under model Mm evaluated at the maximum likelihood
estimates βˆ and dm is the number of terms in the model. Because of the large number of
features and higher order terms, we cannot enumerate all models. To identify the highest
posterior probability models, we used the deterministic search algorithm bic.glm() in S-
PLUS to identify the best BIC models (Hoeting et al. 1999).
Because of the large number of potential features and limitations in the leaps and bounds
algorithm used in bic.glm(), it was necessary to use a two stage procedure to identify which
features would be incorporated in the selected model. The first stage was a screening stage
where we identified the highest probability models that included only linear terms in the
features. Using the subset of features that were included in the top model, we then added
quadratic and cubic terms in these features, and repeated the calculations of the posterior
model probabilities. While such a sequential approach had the potential not to identify the
highest probability model overall, this scheme corresponds to a hierarchical structure that
incorporates second order (and higher) terms only if there are important main (linear) terms.
Secondly, because the search algorithm needed to be run for hundreds of other drugs, this
led to a reasonably efficient computational strategy that could be run on computers at BD.
After this two stage selection approach, the highest posterior probability model was used to
determine the distribution of the MIC, as described in Section 4.
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3.3 Model Fitting Results
The above procedures are applied to study the turbidity and redox growth curves for gram-
negative bacterial strains exposed to dilutions of cefoxitin (FOX) (n = 1647 panels) and
piperacillin (PIP) (n = 1599 panels). These two antibiotics were selected to provide a
testbed for method development. FOX was considered to be an easier system to model,
with more clearly distinguished cases of GROWTH/NO GROWTH, while PIP was viewed
as being a more challenging case. For modelling purposes here, both fast and slow growing
strains were combined.
In modelling GROWTH/NO GROWTH, we have made no effort to constrain the esti-
mated probabilities piij in a panel to be ordered based on dilution. We chose not to constrain
the piij as the actual dilution in a panel may differ from its nominal level leading to ob-
served growth curves that may cross. Rather than explicitly building an order constraint
into the model for GROWTH/NO GROWTH, we take the theoretical ordering into account
in developing the prediction of the MIC, as described in the next section.
4 MIC Estimation
4.1 Overview of MIC Estimation
The modeling described in Section 3 operates at the level of a single well, and is aimed
at determining the probability that each well is displaying growth. Note, however, that
prediction of the MIC must be done at the level of a panel. In this section we describe
our strategy for combining the well-level predictions and obtaining a MIC estimate for each
panel. For panel i, our prediction algorithm consists of the following:
Estimate growth probabilities. For each well j in panel i estimate the probability
piij that there is growth in well j.
11
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Combine growth probabilities. For each well j in panel i estimate the probability
ρij that the dilution present in well j is the MIC. This distribution of the MIC is
constructed by combining all the pˆiij for panel i and is described in detail in Section
4.2.
Estimate the MIC. Using the distribution of the MIC, ρij , derive an estimate for
the MIC in panel i. Two estimates are discussed in detail: the “modal MIC” and a
“decision theoretic MIC”. The probability distribution of the MIC may also be used to
delay the call, when there is a high degree of uncertainty about which dilution is the
MIC.
Statistically, this overall procedure achieves the important practical goals of a) estimating
growth based on simple physical features representing growth in a well; b) training the
growth probability model on large datasets; c) adjusting the probability of growth in a well
depending on the observations made on other wells in the same panel; and d) providing the
basis for sequential estimation of the MIC, and decisions about delaying the call.
4.2 Probability Distribution of the MIC
We now describe how to derive the probabilities ρi1, . . . , ρiJ that the dilution present in each
well is the MIC, using the set of probabilities pˆii1, . . . , pˆiiJ that there is growth in each well.
Suppose that the dilution for well j (denoted as Dj) is the MIC for panel i. If this were true,
theoretically we would have the following sequence of curves: all curves with dilutions less
than Dj would exhibit GROWTH, and all dilutions greater than or equal to Dj would have
NO GROWTH. How do we compute the probability of this sequence given the probability
of GROWTH/NO GROWTH for each well?
First we need to make additional assumptions of order (O) and independence (I):
12
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O: Suppose that the dilution (concentration) in well j, Dj, is greater than the dilution in
well k, Dk. Then, if Dk is inhibitory, so is Dj .
I: The outcome in well j, Yij, is independent of the outcome Yik in any other well k 6= j.
We previously utilized Assumption I in constructing the model for GROWTH/NOGROWTH.
Within the nested restrictions of Assumption O, the probability of the sequence of curves
that can leads to Dj being the MIC, can be computed under independence, Assumption I.
Consider the set of all sequences of growth curves that satisfy the ordering assumption
O. We call these “valid” sequences. For example, if a panel had only three wells, the set of
valid sequences of GROWTH/NO GROWTH results would be
D1 < D2 < D3 MIC
0 0 0 < D1
1 0 0 D2
1 1 0 D3
1 1 1 >D3
By restricting attention to the reduced set of ordered sequences, we are now in a position
to compute the probability ρij of the sequence of curves that leads to Dj being the MIC in
panel i. This ordered sequence is
D1 . . . Dj−1 Dj . . . DJ
1 1 1 0 0 0.
By comparing the likelihood of the sequence above to the likelihood of the other valid se-
quences, we can compute MIC probabilities that are consistent with the ordering assumption
O,
ρij = P (MICi = Dj) =
∏
k<j piik
∏
k≥j(1− piik)∑J+1
j=1
∏
k<j piik
∏
k≥j(1− piik)
(2)
where the denominator is a sum over all J + 1 valid sequences.
13
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For a particular model Mm, this can be estimated by plugging in the pˆiij . To take
into account model uncertainty, one can average the above expression over several models
using the posterior probabilities of models as weights. While such a procedure may give
better estimates, we have not pursued this direction because of the limited capacity for the
PHOENIX system, and instead use the highest probability model.
The probabilities ρij can be used in several ways to determine an estimate of the MIC. We
experimented extensively with two approaches: the “modal MIC” and a “decision theoretic
MIC”. The modal MIC consists simply of choosing the dilution Dj for panel i with the
largest probability ρij. This is the optimal estimator under a loss function that is one if
the estimate is not the true MIC and zero if the estimate is exactly the MIC. Our decision
theoretic MIC takes into account that under-estimation and over-estimation have different
costs and that errors of plus or minus one dilution are unimportant.
4.3 Decision Theoretic MIC Estimation
In evaluating performance in practice, a number of error types are evaluated. The essential
agreement between estimated MICs and reference MICs are defined as agreement in MIC to
within ± 1 dilution, and reflect that errors in estimation of ± one dilution are unimportant.
According to the Food and Drug Administration (FDA 2007, page 21), the essential agree-
ment should be greater than or equal to 90% . In general, underestimation of the MIC by
more than one dilution is considered to be worse than overestimating the MIC by more than
one dilution.
A second approach for evaluating performance utilizes the categorical classification of
isolates as susceptible, resistant or intermediate. The S/I/R interpretations are compared
and categorical agreement is evaluated. Based on FDA guidelines, the overall categorical
agreement should be greater than or equal to 90%. Acceptable error rates are based on the
clinical significance of the error. A very major error (VME) occurs when an isolate is called
14
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sensitive when the isolate is in fact resistant. A VME rate greater than 1.5% of the resistant
strains would be unacceptable. The major error threshold is more forgiving, less than or
equal to 3%, and occurs when an isolate is called resistant when in actuality the isolate is
sensitive. While we do not have the S/I/R classification for the isolates in our study, we can
devise a decision theoretic estimator that captures the ideas behind the categorical errors,
where underestimating the MIC leads to more severe consequences than overestimating it.
One way to capture this is to attach a weight, or a loss, to each dilution error size. We use
the following notation:
Error Loss
Exact prediction (no error) 0
Predicted MIC within 1 dilution of reference MIC w3
Predicted MIC > reference MIC by more than 1 dilution w2
Predicted MIC < reference MIC by more than 1 dilution w1
The w’s need to be chosen to reflect the relative importance of the errors and will typically
be such that w1 > w2 > w3.
To obtain the MIC prediction we choose the dilution that minimizes the expected loss.
For dilution Dj this is
Lj = w1
∑
k>j+1
ρik + w2
∑
k<j−1
ρik + w3
(
ρi(j−1) + ρi(j+1)
)
.
The decision theoretic MIC prediction is the Dj associated with the j that minimizes Lj . If
one chooses w1 = w2 = w3 the modal MIC and the decision theoretic MIC coincide. For the
analyses reported later we used w1 = 5, w2 = 1 and w3 = 0, reflecting that under estimating
the MIC by more than one dilution is 5 times worse than over estimating it by more than
one dilution. There is no penalty for being within one dilution of the reference MIC.
15
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4.4 Uncertainty and Making a Call
The distribution of the MIC may be useful in formulating guidelines for deciding when to
make a call on the MIC prediction or when to continue incubating a panel. One could
determine the modal MIC or decision theoretic MIC and how much probability they receive,
as well as how much probability mass the estimated MIC plus or minus 1 dilution receives.
Sampling could continue until these reach a specified level of confidence. We expect that as
sampling continues, the estimated piij will become closer to 1 or 0, so that the probability
of the model MIC (the dilution with the largest probability) should increase to 1. However,
early on the probabilities will not be as concentrated.
4.5 Illustration
Figure 2 shows the MIC distribution for the three bacterial strains that were presented in the
growth curves in Figure 1, while Table 2 lists the estimates of the MIC and the probability
mass that they receive. For strain 144882, the distribution of the MIC is uni-modal with
TEST ID REF MIC Modal MIC Decision Theoretic MIC
P(REF ±1) P(Modal MIC) P(DT MIC) P(Valid Sequence)
14482 2 2 2
(0.96) (0.47) (0.47) 0.63
14598 2 1 2
(0.90) (0.52) (0.29) 0.74
14617 4 128 128
(0.00) (0.58) (0.58) 0.50
Table 2: MIC prediction results for the three strains of interest. P(REF ±1) represents
the probability that the mass assigned to dilutions within 1 dilution of the reference MIC.
P(Modal MIC) and P(DT MIC) are the probabilities that the modal and the decision the-
oretic MICs estimates are the reference MIC, respectively. P(Valid Sequence) is the sum of
probabilities of all possible valid sequences.
a peak at two, which corresponds to the modal MIC, the decision theoretic MIC and the
reference MIC. For strain 14598, we also have a uni-modal distribution, but underestimate
16
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the MIC by one dilution using the modal MIC (reference MIC = 2, modal MIC = 1), while
the decision theoretic MIC agrees with the reference MIC. Because the estimate is within
one dilution of the reference MIC, this error is not important. Finally for strain 14617, the
modal MIC is 128, while the Reference MIC is 4. While overestimation of the MIC is better
than underestimation, this results in an unacceptably large error. The reference MIC and
dilutions within one of it receive virtually no support under the estimated distribution of
the MIC. Also, the probability of all valid sequences is 0.5 indicating that curves are less
likely to be ordered by dilution than with the other strains, where the probability is 0.63
and 0.74. Recall, however, that in this case there are several curves with dilutions above
the reference MIC that exhibited strong growth. Verification of the reference data indicated
that the response variable is in fact not in error. One possible explanation for the growth is
that the amount of antimicrobial agent in the panel may be less than its nominal level. In
the case of this type of outlier, we feel that the data for the panel may be deleted and the
model refit using the remaining data.
5 Validation
To carry out model validation for each drug, we divide the data into a training and validation
group. We used a random sample of 65% of the panel data for training and the remaining
35% for validation. In the training stage we identify the best model using BIC as described
previously. This model is then used to predict the MICs for the validation group.
The MIC prediction for the validation group proceeds as follows.
1. The features from each dilution j of each panel i in the validation group are used
along with the estimated coefficients from the training data to predict the probability
of growth in each well, pˆiij .
2. The probability that a dilution is the MIC, ρˆij is calculated (see equation (2)). These
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ESTIMATE EST - REF < -1 -1 ≤ EST - REF ≤ 1 EST - REF > 1
Modal MIC 3.99 91.84 4.17
Decision Theoretic MIC 1.57 90.91 7.52
Table 3: Essential agreements from the FOX validation data.
ESTIMATE EST - REF < -1 -1 ≤ EST - REF ≤ 1 EST - REF > 1
Modal MIC 24.46 71.07 4.46
Decision Theoretic MIC 11.61 80.36 8.04
Table 4: Essential agreements from the PIP validation data.
probabilities are estimated by plugging in the estimates of piij obtained in Step (1) for
the panels in the validation set.
3. The estimated MIC probabilities (ρˆij) for each dilution in each panel are then used to
estimate the modal or decision theoretic MIC.
For each panel in the validation set we thus obtain a modal and decision theoretic MIC
estimator.
5.1 Essential Agreements
The essential agreements are summarized graphically in Figures 3 and 4 and in Tables 3 and 4
for the FOX and PIP data. In Figure 3 note that the choice of MIC estimator markedly effects
the error type rates. For the modal MIC the error rate associated with under estimation by
more than one dilution was 3.99% whereas that for the decision theoretic MIC, the error rate
was 1.57%. Essential agreements for the two MIC estimates were similar, 91.84% for the
modal MIC and 90.91% for the decision theoretic MIC. The error rates for PIP are noticeably
higher as anticipated based on initial perceptions of PIP being a more challenging system.
The decision theoretic MIC has a much higher essential agreement than the modal MIC,
with a reduction by half in the underestimation error rate (11.6% versus 24.5%).
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To further explore the errors, a plot of log2(estimated MIC) - log2(reference MIC) versus
the P (MIC = Dj) is given in Figures 3 and 4, where the estimated MIC is either the
modal MIC or decision theoretic MIC. Note that for the decision theoretic MIC in the
FOX data, a probability of less than about 0.4 produces a wider scatter in log2(estimated
MIC) - log2(reference MIC), corresponding to more cases of poor agreement between the
estimated and reference MIC. It is possible that by delaying the call because of the substantial
uncertainty in the MIC and allowing the samples to incubate longer, that we may reduce
such errors.
6 Discussion
In this paper we have illustrated a probabilistic approach for estimating MICs based on
panels of microbial growth curves. Given the necessity to fit a large number of models to
hundreds of antibiotics, we had to make several compromises in our modelling approach due
to the computational environments available at the time and the current computing/storage
constraints of the PHOENIX device. Given advances in computing environments today,
more flexible models could be obtained by replacing the cubic polynomials with piecewise
cubic splines as in generalized additive models (GAM). While a fully Bayesian analysis might
be preferable, the use of approximate model probabilities using BIC and plug-in estimates
provided a solution that could be implemented in real-time in a device with limited computing
and storage capacity.
Despite the potential shortcomings given above, various studies have tested the accuracy
of the PHOENIX AST system and have shown that this system provides accurate estimates
of MICs. Currently, 85 drug indications are cleared by the Food and Drug Administration,
with an additional 20 to 25 in clinical trials. In a European collaborative two-center trial
(Fahr et al. 2003), this system was tested for 469 clinically obtained bacterial isolates with
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64 antimicrobial drugs. The results were compared to those of frozen standard broth micro-
dilution (SBM) panels according to National Committee for Clinical Laboratory Standards’
guidelines. It was found out that the PHOENIX AST performance was equivalent to that of
the SBM reference method. In addition to accuracy in prediction Donay et al. (2004) found
that the PHOENIX AST system required significantly less time to obtain results than by
the disk diffusion method.
Predicting the emergence of antibiotic resistance is a challenging problem that many
automated AST systems fail to adequately address (Tenover et al. 2006). In some cases re-
sistance to higher levels of an antibiotic is virtually unknown. Because the models developed
in this paper predict inhibition of growth based on features of the curves, and not dilution,
the PHOENIX AST system may predict high MICs indicative of emerging resistance, even
though the models have not necessarily been trained on resistant strains. The PHOENIX
system has already proved to be effective in detecting the emergence of Staphylococcal re-
sistance to vancomycin (Deal et al. 2002).
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Figure 1: Panel data for three gram-negative bacterial strains exposed to dilutions of
piperacillin showing turbidity (a) and redox (b) over time in hours. The vertical line is
at the time-to-result when features are extracted for estimating the MIC. All curves in red
have concentrations less than the reference MIC, while those in blue have concentrations
greater than or equal to the reference MIC.
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Figure 2: Probability distribution of the MIC for the three strains presented in Figure 1. The
bars in red represent dilutions below the reference MIC, while the bars in blue correspond
to dilutions greater than or equal to the reference MIC.
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Figure 3: Essential agreement (top) and residual plots (bottom) for FOX validation set using
the Modal MIC (left) and the Decision Theoretic MIC (right).
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Figure 4: Essential agreement (top) and residual plots (bottom) for PIP validation set using
the Modal MIC (left) and the Decision Theoretic MIC (right).
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